Repatha plus standard care for heart disease in Chinese patients
Part of Brain & nervous system, Heart & circulation, Pain clinical trials.
This study tests whether adding Repatha (a weekly injection that lowers cholesterol) to your usual heart medications can reduce the risk of future heart attacks, strokes, or other heart problems. It is for people who have already had a heart attack or stroke, or have certain high-risk conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a heart attack or stroke, or you have symptoms of peripheral artery disease (like leg pain when walking).
- Your LDL ('bad') cholesterol was 70 mg/dL or higher in the last 6 months, or your non-HDL cholesterol was 100 mg/dL or higher.
- Your triglycerides (another type of fat) were 400 mg/dL or lower in the last 6 months.
- You have not had a stroke in the last month.
- You have not used Repatha or similar cholesterol-lowering injections in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a PCSK9 inhibitor to standard statin therapy can help people with narrowing in brain arteries that hasn't caused symptoms yet. The goal is to see if this combination lowers plaque and prevents future strokes.
This trial tests a new medicine called SRSD216 for people with high levels of lipoprotein (a), a type of fat in the blood that can increase heart disease risk. The study aims to see if the drug is safe and effective at lowering these levels.
This trial tests whether a PCSK9 inhibitor (a drug that lowers cholesterol) can help people who recently had a stroke caused by narrowing of an artery inside the skull. It aims to see if the drug can prevent more strokes and improve recovery.
This trial tests a smart computer tool that helps doctors manage your cholesterol treatment with Evolocumab (Repatha). If you have had a recent stroke or mini-stroke and are already taking this medicine, the tool may help you reach your LDL (bad cholesterol) goal faster.
This study tests whether lowering cholesterol to very low levels (below 1.0 mmol/L) is more beneficial and safe than a slightly higher target (1.0–1.39 mmol/L) in patients with severe, recurrent heart or stroke events. You'll receive cholesterol-lowering medications and regular monitoring to see which target works best.
This trial tests whether quickly starting an aggressive cholesterol-lowering treatment after a stroke improves recovery. It is for people who are about to have a procedure to remove a large blood clot from their brain.
Hear when a new Major Cardiovascular Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.